1. Introduction {#sec1}
===============

Aortic valve replacement (AVR) in elderly patients can be performed with excellent results and can improve survival when compared with medical therapy for patients with aortic stenosis \[[@B1]--[@B3]\]. However, little is known regarding postoperative recovery and subsequent quality of life (QOL) in patients who undergo either isolated AVR or AVR associated with other procedures such as coronary artery bypass grafting (CABG). For instance, controversy continues to exist regarding the value of aortic valve replacement in older patients whose lifestyles and activities may be limited by their ages or comorbidities. We used echocardiography (ECHO), bicycle cardiopulmonary exercise testing (CPET), and QOL surveys to evaluate elderly patients after AVR for aortic stenosis with the Hancock II porcine bioprosthesis (Medtronic Inc., Minneapolis, MN).

2. Methods {#sec2}
==========

This prospective study was approved by the institutional review board, and written informed consent was obtained from all study participants. All patients underwent transthoracic echocardiography (TTE) and completed the RAND 36-Item Health Survey (SF-36) as part of their preoperative evaluation. Six months later they underwent repeat TTE combined with CPET and completed a second SF-36.

2.1. Aortic Valve Replacement {#sec2.1}
-----------------------------

All patients underwent open aortic valve replacement using standard cardiopulmonary bypass techniques and the Hancock II porcine bioprosthesis (Medtronic Inc.). After complete debridement of the aortic annulus via a transverse aortotomy, manufacturer provided valve sizers were used to select the valve size that most closely approximated the aortic outflow orifice while sitting comfortably in the supra-annular position. The valve was then implanted using synthetic sutures reinforced with teflon felt pledgets on the ventricular side. Transesophageal echocardiography was utilized after weaning from cardiopulmonary bypass to assure adequate valve function and to assess for perivalvular leaks. Postoperative anticoagulation was limited to ASA only for patients in sinus rhythm.

2.2. CPET Protocol with Bicycle Ergometer {#sec2.2}
-----------------------------------------

Peak exercise capacity is defined as the "maximum ability of the cardiovascular system to deliver oxygen to exercising skeletal muscle, and of the exercising muscle to extract oxygen from the blood \[[@B4]\]." Exercise capacity is determined by (1) pulmonary gas exchange, (2) cardiovascular performance, (3) and skeletal muscle metabolism. Prior to recording data, a clamp was placed on the nose and the patient breathed through a mouthpiece attached to a nonrebreathing valve. Expired air was collected through the valve into a mixing chamber and sampled continuously by fast responding oxygen and carbon dioxide analyzers. This method uses a distributive processing technique involving a waveform analyzer and a host computer. Respiratory gas exchange was obtained on a breath by breath analysis.

CPET was conducted on an upright bicycle ergometer utilizing a ramp protocol with increments of 10--15 watts per minute \[[@B5]\]. Baseline measurements were established during three minutes of rest and three minutes of unloaded cycling. Testing was ended when *V* ~O~2~~ *Max*⁡, the maximum capacity of an individual during incremental exercise to transport and utilize oxygen, was obtained. Breath analysis was used to measure respiratory gas exchange through obtaining *V* ~O~2~~ and central venous oxygen saturation (CVO~2~). Ventilation, the rate that air is exchanged between the lungs and the environment, was also measured through breath analysis. Peak *V* ~O~2~~ was determined and the minute ventilation-carbon dioxide production (VE/CVO~2~) slope was used to estimate the anaerobic threshold (AT).

Workload and max heart rate (HR) and blood pressure (BP) were also measured. AT, the point during exercise where muscles derive energy from nonoxygenic sources, of \<40% of the predicted peak *V* ~O~2~~ was considered pathologically reduced and indicative of circulatory insufficiency. A respiratory exchange ratio, the ratio of carbon dioxide to percent oxygen in a breath, of \<1.0 in the absence of other metabolic abnormalities suggested poor effort or anxiety, because the ratio of carbon dioxide is expected to increase with exercise. Determination of peak *V* ~O~2~~ was derived as the average of two consecutive 15- or 20-second segments from the last minute of exercise with the highest average value. CPET results for each patient were compared with those from predicted normal patients of a similar age as described by Fleg and Lakatta \[[@B6]\].

2.3. Doppler ECHO {#sec2.3}
-----------------

Color flow Doppler ECHO of the prosthetic aortic valve in each patient was performed at rest and immediately after peak *V* ~O~2~~ was reached with CPET. Mean and peak gradients were measured. We also measured left ventricular function via ejection fraction on ECHO.

2.4. Quality of Life {#sec2.4}
--------------------

Patients completed the SF-36 survey pre- and postoperatively at six months. The SF-36 is a short-form health survey with eight sections describing functional health and well-being. It includes psychometrically based physical and mental health scores. The SF-36 is a generic tool that can be used for any population or age group. We used matched pairs *t*-tests to compare preoperative to postoperative SF-36 scores in order to assess improvement in QOL \[[@B7], [@B8]\].

3. Results {#sec3}
==========

Thirty three patients underwent aortic valve replacement with a porcine Hancock II bioprosthesis. The average age was 75.3 ± 5.3 years (24 men and 9 women). NYHA functional class pre- and postoperatively is shown in [Table 1](#tab1){ref-type="table"}. Twenty-three concomitant procedures were completed as follows: 12 CABG, three ascending aorta replacements, two mitral valve repairs, two mazes, one ASD closure, one carotid endarterectomy, one PFO closure, and one SVC enlargement.

3.1. Hemodynamic Results {#sec3.1}
------------------------

Mean pressure gradient at rest and during exercise and BSA are depicted in [Table 2](#tab2){ref-type="table"} according to valve size. [Figure 1](#fig1){ref-type="fig"} displays the postoperative ejection fractions for our patients.

3.2. Bicycle CPET {#sec3.2}
-----------------

Patients had a mean predicted maximum *V* ~O~2~~ (mL/kg/min) of 19.5 ± 4.3 and an actual max *V* ~O~2~~ of 15.5 ± 3.9, which was 80% of the predicted *V* ~O~2~~. The expected maximum *V* ~O~2~~ used for a healthy 75-year-old person was 19 mL/kg/min predicted and 15 mL/kg/min actual, resulting in 80% of the predicted *V* ~O~2~~ for a healthy subject \[[@B6], [@B9]\]. The max *V* ~O~2~~ values for our patients are displayed in [Figure 2](#fig2){ref-type="fig"}. AT greater than 55% of the max *V* ~O~2~~ is thought to be a normal response \[[@B10], [@B11]\].

3.3. RAND SF-36 Survey Results {#sec3.3}
------------------------------

Patients showed statistically significant improvements (*P* ≤ 0.01) in six of nine health parameters outlined by the QOL survey. Results from the SF-36 survey are shown in [Table 3](#tab3){ref-type="table"}.

4. Discussion {#sec4}
=============

The Hancock II (Medtronic Inc.) is a second generation supra-annular porcine bioprosthesis with a proven history of excellent durability and acceptable hemodynamic performance \[[@B12]\]. Though third generation bioprostheses are currently available and have been designed with improved durability and hemodynamics in mind, they are significantly more expensive and their advantages remain controversial. While pericardial aortic bioprostheses are known to have improved hemodynamics over their porcine counterparts, this does not necessarily translate into improved survival or left ventricular mass regression \[[@B13]\]. Furthermore, long-term studies comparing the durability of third generation valves (with new anticalcification agents) with their second generation counterparts are not yet available. The result is that the Hancock II continues to see widespread use, both in the United States and other countries where price and availability may take on greater roles.

We evaluated aortic valve replacement with the Hancock II porcine bioprosthesis in elderly patients with aortic stenosis with regard to symptom improvement and quality of life, exercise tolerance, and prosthetic hemodynamic performance. Our study is one of the few that contributes to both subjective and objective assessment of the benefits of valve replacement in the elderly.

In vivo comparisons of bioprosthetic valves can be difficult, due to the clinical and hemodynamic variability that occur between measurements \[[@B14], [@B15]\]. Whereas one year seems to be the preferred followup for echocardiographic analysis of bioprosthetic hemodynamics, we chose six months because we were primarily interested in early recovery from aortic valve surgery with regard to exercise capacity and quality of life. We limited our echocardiographic analysis to mean pressure gradients and EOA, given their common use in surgical studies of this kind.

The exercise hemodynamics in our patients showed a lower mean pressure gradient by labeled valve size than patients with bioprosthetic valves in other studies. Eichinger et al. looked at the Medtronic Mosaic valve in 2005 and found that the mean pressure gradients at maximum stress (75 watts) were 25.1, 25.7 ± 5.6, and 20.2 ± 8.0 for valves sized 21 mm, 23 mm, and 25 mm, respectively \[[@B16]\]. Our results show a lower mean pressure gradient for the 23 mm valve (20.1 ± 8.1) and the 25 mm valve (20.1 ± 10.2). We found a higher mean pressure gradient for the 21 mm valve (27.2 ± 14.0) compared to 25.1 found by Eichinger. However, this result in the Eichinger study was a single patient. Overall, our results show similar mean pressure gradients to previous studies that evaluated porcine bioprostheses \[[@B16], [@B17]\]. We also found a decrease in pressure gradients at both rest and peak exercise with an increase in valve size, which is consistent with existing literature.

Our patients demonstrated similar predicted and actual maximum *V* ~O~2~~ measurements to the expected normal aging population \[[@B6], [@B9]\]. They were also found to have an AT greater than 55% of the maximum *V* ~O~2~~, which is consistent with a normal response \[[@B10], [@B11]\]. The fact that our patients had exercise testing results that were within normal limits for their age suggests that these patients had an excellent functional response to AVR.

To evaluate quality of life, we employed the SF-36 survey, which has been shown to have a high discriminatory power as well as test-retest reliability and construct validity \[[@B7], [@B8], [@B18]\]. We found that patients showed significant improvements (*P* ≤ 0.01) in QOL six months postoperatively in six of the nine SF-36 health parameters: physical functioning, role limitations due to health, energy-fatigue, social functioning, general health, and health change. This result suggests that the patients in our study had a significant decrease in symptoms and overall improvement in QOL.

Subjective assessment of QOL is an uncommonly used but important method of assessment of postsurgical evaluation. In fact, others have found that only 3.6% of cardiovascular randomized controlled trials reported QOL data, and when QOL results are reported, if they are discordant, authors will not look at QOL data in relation to the other study outcomes \[[@B19], [@B20]\]. Our QOL results show significant and meaningful improvements for patients after valve replacement. These results are consistent with results from other studies that have found QOL improvement in elderly patients with bioprosthetic heart valve replacement \[[@B21]--[@B23]\].

Our study had several limitations. First, our in vivo ECHO analysis was six months after surgery, as opposed to one year that has been used to evaluate bioprosthetic hemodynamics in other studies. However, we were interested in studying early recovery to compare with quality of life metrics. Second, while a midterm analysis with exercise capacity would be ideal in terms of long-term performance evaluation, this analysis was outside of the scope of our study.

We found that replacing a stenotic aortic valve with a Hancock II porcine bioprosthesis resulted in low mean pressure gradients during both rest and peak exercise, above average exercise capacity at six months postoperatively, and significant improvement in overall quality of life. Given the excellent durability recently reported with this valve, the Hancock II remains an excellent option for aortic valve replacement in elderly patients \[[@B3]\].
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###### 

NYHA Functional Classification.

  Functional Classification   Pre-op     Post-op
  --------------------------- ---------- ----------
  FC I                        1 (3%)     27 (82%)
  FC II                       5 (15%)    6 (18%)
  FC III                      27 (82%)   ---
  FC IV                       ---        ---

###### 

Post-op ECHO results.

  ----------------------------------------------------------------------------------------------------
  Valve size\   Number of patients   Mean gradient\   Mean gradient at exercise (mmHg)   BSA (m^2^)
  (mm)                               at rest (mmHg)                                      
  ------------- -------------------- ---------------- ---------------------------------- -------------
  21            5                    14.2 ± 5.5       27.2 ± 14.0                        1.88 ± 0.15

  23            13                   12.4 ± 5.9       20.1 ± 8.1                         2.01 ± 0.15

  25            14                   10.1 ± 3.7       20.1 ± 10.2                        2.05 ± 0.17

  27            1                    12               17                                 1.8

  All sizes     33                   11.7 ± 5.0       21.1 ± 10.0                        2.0 ± 0.17
  ----------------------------------------------------------------------------------------------------

###### 

SF-36 QOL.

  Health parameters                          Items   Pre-op    Post-op   *P* value
  ------------------------------------------ ------- --------- --------- -----------
  Physical functioning                       10      52 ± 27   73 ± 24   ≤0.001
  Role limitations due to physical health    4       32 ± 40   72 ± 36   ≤0.001
  Role limitations due to emotional health   3       61 ± 40   74 ± 38   0.096
  Energy-fatigue                             4       54 ± 22   68 ± 20   ≤0.001
  Emotional well-being                       5       78 ± 16   81 ± 16   0.264
  Social functioning                         2       74 ± 28   88 ± 18   ≤0.001
  Pain                                       2       75 ± 28   82 ± 22   0.068
  General health                             5       66 ± 16   75 ± 13   0.01
  Health change                              1       32 ± 22   80 ± 23   ≤0.001

[^1]: Academic Editor: Frans Leenen
